The rest is here:
CORRECTING AND REPLACING - LAVA Therapeutics to Present Corporate Overview at 40th Annual J.P. Morgan Healthcare Conference

Read the rest here:
Aileron Therapeutics Issues Statement on Passing of Scientific Advisory Board Member and Nobel Laureate Robert H. Grubbs

Read more:
Women In Bio Elects Dr. Azurii Collier as 2022 President-Elect

Here is the original post:
Cosmos Holdings Announces Shareholder Approval of Private Offering

See the rest here:
Statera Biopharma Announces First Patient Dosed in Study of STAT-205 for Acute COVID

Link:
Terranueva is Granted a New Category of Licence to Sell Cannabis

Read more from the original source:
CytomX Therapeutics Announces Preliminary Results for Ongoing Phase 2 Expansion Study of CX-2029, a First-in-Class Antibody-Drug Conjugate Candidate...

Read the original here:
Progenity Completes Exit from Laboratory Business with Sale of Affiliate Lab

Read the rest here:
scPharmaceuticals to Participate in Two Upcoming Investor Conferences

Go here to see the original:
Kinnate Biopharma Inc. to Present Updates from its Lead RAF and FGFR Inhibitor Candidate Programs at Upcoming Scientific Meetings

Read the rest here:
Osmotica Pharmaceuticals plc to Present at H.C. Wainwright Bioconnect Conference

See the original post here:
Opiant Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Originally posted here:
Sandoz submits Biologics License Application for proposed biosimilar trastuzumab to US FDA

Follow this link:
DBV Technologies Provides Update on Investigational Viaskin™ Peanut

Continued here:
BioDelivery Sciences Prevails in BELBUCA® ANDA Litigation Maintaining Patent Exclusivity Against Alvogen Until 2032

See the article here:
First Patient Dosed in Study of Targeted Alpha Therapy Candidate for Bladder Cancer

Link:
Aquestive Therapeutics Receives Notification from FDA that It Will Not Be Ready to Take Action by December 23, 2021 for the Company’s NDA for...

Here is the original post:
Sanofi to acquire Amunix immuno-oncology pipeline with next generation Conditionally Activated Biologics

Read the original post:
Basilea receives USD 10 million milestone payment related to approval of antifungal Cresemba® (isavuconazole) in China

See original here:
Acacia Pharma Issues Ordinary Shares to its Employee Benefit Trust